Categories Earnings, Technology

Nutanix (NTNX) beats top and bottom line estimates for Q1 2020; stock advances

Nutanix (NASDAQ: NTNX) reported better-than-expected financial results for the first quarter of 2020. The company reported a non-GAAP loss of $0.71 per share on revenue of $314 million. Analysts had estimated the cloud computing firm to report a loss of $0.75 per share on revenue of $306.41 million. Nutanix stock jumped more than 15% during the after-market session.

Nutanix (NTNX) beats top and bottom line estimates for Q1 2020; stock advances

On a GAAP basis, Nutanix reported a loss of $1.21 per share in the first quarter of 2020 compared to a GAAP net loss per share of $0.54 in the first quarter of fiscal 2019. Software and Support revenue grew 9% year-over-year to $305 million. Software and Support billings were up 5% to $370.3 million.

Nutanix ended the fourth quarter of fiscal 2019 with 14,960 total customers and closed a record high of 66 deals worth more than $1 million.

For the second quarter of 2020, Nutanix expects non-GAAP net loss per share of approximately $0.70. Software and Support revenue is targeted to be between $330 million and $335 million and Software and Support billings is expected to be between $410 million and $420 million.

For fiscal 2020, the San Jose, California-based tech firm expects Software and Support billings of $1.65 billion and $1.75 billion and Software and Support revenue to be in the range of $1.30 billion and $1.40 billion.

“Our last two quarters of solid execution position us well to deliver on our growth plans for fiscal 2020”, said CFO Duston Williams.

Nutanix shares have gained 46% in the past three months and have dropped 31% since the beginning of 2019.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top